| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers G > Headlines for GlaxoSmithKline plc > News item |
GlaxoSmithKline: HPV 16/18 L1 vaccine with AS04 induces strong immune response
By E. Janene Geiss
Philadelphia, Nov. 1 - GlaxoSmithKline said that data from studies of its investigational human papillomavirus (HPV) 16/18 L1 vaccine formulated with innovative adjuvant AS04 induced a stronger immune response when compared to the same vaccine formulated with aluminum salt alone.
The data was presented Tuesday at the American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research in Baltimore and concurrently at ECCO 10, the congress of the Federation of European Cancer Societies in Paris, according to a company news release.
The vaccine with AS04 had a stronger response that was sustained more than 3½ years post-vaccination in women, officials said.
The results were based on three separate assessments, including in-vitro evaluation on biological activity of AS04, induction of anti-HPV 16 and HPV 18 antibodies and inhibition of major neutralizing epitopes in animal and human subjects, officials said.
"In the field of vaccinology, GlaxoSmithKline continues to innovate. GSK has been developing new adjuvant systems for more than a decade. For our cervical cancer vaccine we pursued the objective of inducing a strong immune
response and protection that lasts," said Gary Dubin, vice president, HPV Vaccines, GlaxoSmithKline, in the release.
HPV is the leading cause of cervical cancer. Seventy seven percent of all cervical cancer cases in the United States and Australia are associated with only two oncogenic types, HPV 16 and HPV 18, officials said.
GlaxoSmithKline's cervical cancer vaccine candidate targeting these two oncogenic HPV types is currently undergoing phase III clinical trials involving more than 28,000 women worldwide.
London-based GlaxoSmithKline is a research-based pharmaceutical and health care company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.